comprehensive -WSS

comprehensive

author：fashion 2025-10-02 01:07:14 - browse：9638

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Biotech reporter’s notebook: A sunnier mood at JPM 2024

entertainment

hotspot

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Abortion pill case raises question: who can sue the FDA?

Heart disease and mental health: A look at cardiac psychology

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

States should stop sabotaging methadone treatment reform

entertainment

comprehensive

hotspot

Activists slam private health insurers over coverage restrictions

Abortion pill case raises question: who can sue the FDA?

Moonlake's readout produced a cash windfall. Risks remain

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Bright Health sells Medicare Advantage business to Molina

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

State Dept. review finds Biden bears some blame for Afghanistan failures

New Medicare drug pricing powers could soon be upended in court

In Memoriam: Notable people who died in 2023

Why the world’s most expensive drug might be worth the price

hotspot

Steward Health Care has deal to sell doctor network to UnitedHealth

Supreme Court mifepristone arguments center on docs' right to sue

Vertex Pharmaceuticals may move headquarters in Boston

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

entertainment

focus

hotspot

leisure time